CANNABIDIOL USE IN CHILDREN WITH DRAVET SYNDROME: A LITERATURE REVIEW
DOI:
https://doi.org/10.47820/recima21.v3i3.1230Keywords:
dravet, dravet syndrome, dravet syndrome and cannabidiol, mechanism of action of cannabidiol epilepsy, cannabidiol epilepsyAbstract
Introduction: Dravet Syndrome is a drug-resistant epileptic encephalopathy and presents 3 phases, which lead to cognitive and behavioral impairments. Due to the ineffectiveness of existing drugs and the need for new therapeutic measures, the interest in the use of cannabidiol arose. Materials and methods: the keywords Dravet syndrome; Dravet; Dravet pharmacology; Dravet syndrome and cannabidiol; Cannabinoids epilepsy were used. The following databases were used: PubMed, Portal de periódicos da Capes and Google Acadêmico. The inclusion criteria for the articles were: articles published in Portuguese and English between 2011 and 2021 and with minimum qualis B3 that were consulted in the Sucupira Platform. Articles whose work objectives did not align with the interests of this research were excluded. Results: Among the 53 articles selected for analysis, only 22 were used as the final sample of the research. Among them, 12 dealt exclusively with Dravet syndrome and its clinical aspects. It was found, in 10 articles, the relationship between Dravet syndrome and the use of cannabidiol as a treatment for the mitigation of seizures. In addition, the articles also highlight other aspects related to the pathology, such as other drug options. Conclusion: The use of the active ingredient CBD is effective for one of the main symptoms of Dravet syndrome, the seizures, and is being increasingly studied due to its high efficacy.
Downloads
References
WYERS, Lore et al.The mechanics behind gait problems in patients with Dravet Syndrome. Gait & Posture , v. 84, p. 321-328, 2021.
Guerrini R, Striano P. Dravet syndrome. Neurology. v. 87, p. 245-246, 2016.
DRAVET, C. Dravet Syndrome History. Developmental Medicine & Child Neurology, v. 53, p. 1-6, 2011.
WHELESS, James W.; FULTON, Stephen P.; MUDIGOUDAR, Basanagoud D.Dravet Syndrome: A Review of Current Management: Pediatric Neurology. V. 107, p. 28-40, 2020
KAPLAN, Joshua S et al. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Pnas. [s.l.], v.114, n.42, p. 11229-11234, Out. 2017.
GAILY, E et. al. Dravet syndrome: New potential genetic modifiers, imaging abnormalities, and ictal findings. Epilepsia, v.54, p. 1577-1585, 2013.
MARINI, Carla et al. The genetics of Dravet syndrome. Epilepsia, v. 52, p. 24-29, 2011.
DEVINSKY, Orrin et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England Journal Of Medicine. [s.l.], v.376, n.21, p. 2011-2020, Mai/Mai. 2017.
MELLIS, Craig. Cannabidiol for drug‐resistant seizures in the Dravet syndrome. Journal of paediatrics and child health, v. 54, n. 1, p. 101-102, 2018.
CROSS, J. Helen et al. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia, v. 60, p. S39-S48, 2019.
DEVINSKY, Orrin et al. Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial. Epilepsia, v. 60, n. 2, p. 294-302, 2019.
LEO, Antonio; RUSSO, Emilio; ELIA, Maurizio. Canabidiol e epilepsia: Justificativa e potencial terapêutico. Pesquisa farmacológica , v. 107, p. 85-92, 2016.
BATTAGLIA, Domenica et al. Delineando um fenótipo neuropsicológico central para a síndrome de Dravet. Epilepsy research , v. 120, p. 91-97, 2016.
O'CONNELL, Brooke K .; GLOSS, David; DEVINSKY, Orrin. Canabinóides na epilepsia resistente ao tratamento: uma revisão. Epilepsy & Behavior , v. 70, p. 341-348, 2017.
GREY, Royston A .; WHALLEY, Benjamin J. Os mecanismos de ação propostos do CBD na epilepsia. Epileptic Disorders , v. 22, p. S10-S15, 2020.
DEVINSKY, Orrin et al. Teste de canabidiol para convulsões resistentes a medicamentos na síndrome de Dravet. New England Journal of Medicine , v. 376, n. 21, pág. 2011-2020, 2017.
WILLIAMS, Claire M.; STEPHENS, Gary J. Development of cannabidiol as a treatment for severe childhood epilepsies. British Journal of Pharmacology, v. 177, n. 24, p. 5509-5517, 2020.
BENDER, Alex C. et al. Mutações SCN1A na síndrome de Dravet: impacto da disfunção do interneurônio nas redes neurais e no resultado cognitivo. Epilepsy & Behavior , v. 23, n. 3, pág. 177-186, 2012.
DEVINSKY, Orrin et al. Ensaio de segurança randomizado com variação de dose de canabidiol na síndrome de Dravet. Neurology , v. 90, n. 14, pág. e1204-e1211, 2018.
FRIEDMAN, Daniel; DEVINSKY, Orrin. Cannabinoids in the treatment of epilepsy. New England Journal of Medicine, v. 373, n. 11, p. 1048-1058, 2015.
BRUNKLAUS, Andreas; ZUBERI, Sameer M. Dravet syndrome—from epileptic encephalopathy to channelopathy. Epilepsia, v. 55, n. 7, p. 979-984, 2014.
ALI, Shayma; SCHEFFER, Ingrid E .; SADLEIR, Lynette G. Eficácia dos canabinóides na epilepsia pediátrica. Developmental Medicine & Child Neurology , v. 61, n. 1, pág. 13-18, 2019.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
